EP Patent

EP4083027A1 — A solid state form of tafamidis and a process for its preparation

Assigned to Quimica Sintetica SA · Expires 2022-11-02 · 4y expired

What this patent protects

A crystalline form of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid and a method for its preparation are described.

USPTO Abstract

A crystalline form of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid and a method for its preparation are described.

Drugs covered by this patent

Patent Metadata

Patent number
EP4083027A1
Jurisdiction
EP
Classification
—
Expires
2022-11-02
Drug substance claim
No
Drug product claim
No
Assignee
Quimica Sintetica SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.